AZD-8330

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H17FIN3O4
Molecular Weight	461.2268
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC2=CC=C(I)C=C2F

InChI

InChIKey=RWEVIPRMPFNTLO-UHFFFAOYSA-N

InChI=1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)

HIDE SMILES / InChI

Molecular Formula	C16H17FIN3O4
Molecular Weight	461.2268
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800026144 | https://www.drugbank.ca/drugs/DB06061 | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=543526

AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers. AZD-8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. AZD-8330 had been in phase I clinical trials by AstraZeneca for the treatment of malignancies. However, this research has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 4 Target ID: CHEMBL2111289 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24840079 \| https://www.ncbi.nlm.nih.gov/pubmed/15853648 \| http://www.eurodiagnostico.com/media/pdf/AZD8330.pdf	Inhibitor 8297		7.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: http://adisinsight.springer.com/drugs/800026144 https://clinicaltrials.gov/ct2/show/NCT00454090	Primary		Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
113.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	AZD-8330 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
160 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
69.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
160 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	60 mg 1 times / day single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
252.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	AZD-8330 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
351.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
186 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
329.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	60 mg 1 times / day single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23433846	60 mg 1 times / day single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:		AZD-8330 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY107062	https://www.001chemical.com/chem/search?q=DY107062
1PlusChem LLC	1P00GUHW	https://www.1pchem.com/search?query=1P00GUHW
AK Scientific	SYN1195	https://aksci.com/item_detail.php?cat=SYN1195
AK Scientific	SYN5687	https://aksci.com/item_detail.php?cat=SYN5687
AK Scientific	X7393	https://aksci.com/item_detail.php?cat=X7393
AOBIOUS INC	AOB87392	http://aobious.com/aobious/search?search_query=AOB87392
ApexBio Technology	A8374	https://www.apexbt.com/catalogsearch/result/?q=A8374
Axon MedChem	1999	https://www.axonmedchem.com/product/1999
BLD Pharm	BD556726	http://www.bldpharm.com/search/Search.html?keyword=BD556726
BOC Sciences	869357-68-6	http://www.bocsci.com/description.asp?cas=869357-68-6
Cayman Chemical	11588	http://www.caymanchem.com/app/template/Product.vm/catalog/11588
Chem Scene	CS-0217	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0217
ChemShuttle	112420	https://www.chemshuttle.com/catalogsearch/result/?q=112420
Excenen	EX-A2349	http://www.excenen.com/searchresultlist.php?id=EX-A2349
KeyOrganics	AS-16990	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16990
Matrix Scientific	132621	http://www.matrixscientific.com/132621.html
MedChem Express	HY-12058	https://www.medchemexpress.com/search.html?q=HY-12058&ft=&fa=&fp=
MolPort	MolPort-016-633-271	https://www.molport.com/shop/molecule-link/MolPort-016-633-271
Molcore	MC107062	http://www.molcore.com/CatMC107062.html
Molnova	M16314	https://www.molnova.com/en/serch-list.html?keywords=M16314
Ryan Scientific	101-93990	https://ryansci.com/products?q=101-93990&list_q=&search_type=exact
Selleck Chemicals	S2134	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2134
ShangHai Biochempartner	BCP000375	http://www.biochempartner.com/search_BCP000375
ShangHai Biochempartner	BCP02466	http://www.biochempartner.com/search_BCP02466
TargetMol	T6083	https://www.targetmol.com/search?keyword=T6083
eMolecules	32278162	https://orderbb.emolecules.com/search/#?query=32278162
eNovation Chemicals	D371092	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D371092&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-7441544217	https://mcule.com/MCULE-7441544217/

PubMed

Title	Date	PubMed
		252160640

Patents

Sample Use Guides

In Vivo Use Guide

Patients with refractory cancer or cancer with no standard therapy received either once-daily (OD) or twice-daily (BID) oral AZD-8330 on day 1 followed by a 7-day washout period and continuous dosing from day 8. The starting dose was 0.5 mg with dose escalations in subsequent cohorts until a non-tolerated dose was reached. The MTD was defined as 20mg BID.

Route of Administration: Oral

In Vitro Use Guide

AZD-8330 potently and strongly inhibits MEK 1/2. AZD-8330 has no inhibitory activity against over 200 other kinases including at concentrations up to 10 uM. AZD-8330 demonstrates sub-nanomolar potency in mechanistic (pERK) and low to sub-nanomolar potency in functional (proliferation) assays in MEK 1/2 inhibitor sensitive cell lines.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:40:11 GMT 2023` Edited by `admin` on `Sat Dec 16 05:40:11 GMT 2023`
Record UNII	G4990BOZ66
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-8330

Common Name

English

ARRY-424704

Common Name

English

AZD8330

Common Name

English

ARRY-704

Common Name

English

2-(2-FLUORO-4-IODOPHENYLAMINO)-N-(2-HYDROXYETHOXY)-1,5-DIMETHYL-6-OXO-1,6-DIHYDROPYRIDINE-3-CARBOXAMIDE

Systematic Name

English

AZD 8330

Common Name

English

AZD 8330 [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

16666708